Ovarian cancer (OC), one of the three most common gynecological malignancies, is characterized by low early detection rates and poor prognosis. Patients with OC face a high risk of developing transcoelomic metastasis—the spread of cancer cells within the abdominal cavity—during the early stages of the disease, a process strongly linked to poor survival outcomes. However, the underlying mechanisms of how OC cells spread from the primary tumor to distant sites have remained elusive.

In a recent study published in Genes & Diseases, researchers from Tianjin Medical University, Tianjin Central Hospital of Gynecology Obstetrics, and Nankai University, employed CRISPR-based large-scale genetic screening alongside an orthotopic ovarian cancer mouse model with gene knockout cells to unravel the molecular mechanisms underlying OC.

Using a genome-wide in vivo CRISPR/Cas9 screening approach combined with patient-derived transcriptomic datasets, researchers identified neuroblastoma suppressor of tumorigenicity 1 (NBL1) as one of the most critical genes promoting transcoelomic metastasis. NBL1 was found to be significantly overexpressed in metastatic ovarian tumors, with expression levels strongly correlating with advanced clinical stage and poor survival outcomes.

Further experiments by the team revealed that NBL1 promotes OC cell proliferation, migration, invasion, and resistance to apoptosis through dual mechanisms: i) direct activation of Jak/Stat3 signaling via physical interaction and ii) suppression of anti-tumor immunity by limiting T cell infiltration. Notably, the Stat3 inhibitor Wp1066 was shown to block NBL1-driven metastasis, reversing its effects on cell proliferation, migration, and epithelial–mesenchymal transition (EMT), both in in vitro and in vivo models.

In conclusion, this study reveals a previously unrecognized oncogenic role of NBL1 in OC metastasis through Jak/Stat3 pathway activation. Its strong association with poor prognosis, combined with reversibility by Stat3 inhibitors, positions NBL1 as both a prognostic biomarker and a promising therapeutic target.

Reference

Title of Original Paper: A systematic CRISPR screen reveals an NBL1-mediated Jak/Stat3 crosstalk to promote ovarian cancer metastasis

Journal: Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101740

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4 | Impact Factor: 9.4

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases)